Results of conservative treatment of locally advanced larynx squamous cell carcinoma using intraarterial regional polychemotherapy

Author:

Safarov D. A.1ORCID,Mudunov A. M.2ORCID,Dolgushin B. I.1ORCID,Akhundov A. A.1ORCID,Zaderenko I. A.1ORCID,Peshko D. A.1ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

2. Lapino Clinical Hospital

Abstract

The study objective is to evaluate the results of organ-preserving treatment of locally advanced larynx squamous cell carcinoma.Materials and methods. Analysis of 28 patients with locally advanced larynx squamous cell carcinoma (stages III-IV) who underwent treatment at the N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia between 2017 and 2020 was performed. At the first stage, 2-3 courses of combined inductive polychemotherapy per the DCF scheme with 21-day interval were performed (docetaxel 60 mg/m2, cisplatin 60 mg/m2 intraarterially bolus with detoxication with sodium thiosulfate, 5-fluorouracil 1000 mg/m2/day as 96-hour infusion). The second stage included external beam radiotherapy (60-70 Gy, 2 Gy per day 5 days a week) as monotreatment if complete clinical response after chemotherapy was achieved or with regional administration of cisplatin (60 mg/m2 once per 3 weeks) if after inductive stage full clinical response wasn»t observed.Results. In 20 (71.5 %) patients, complete clinical response was observed after inductive treatment; in 7 (25 %) patients, partial response was observed. Tumor stabilization was detected in 1 (3.5 %) patient. Two-year overall survival was 95.8 ± 4.1 %, progression-free survival was 90.1 ± 6.8 %.Conclusion. The proposed strategy of organ-preserving treatment of stage III-IV larynx cancer with substitution of systemic chemotherapy with regional intraarterial chemotherapy prior to radiotherapy is highly effective from the point of view of direct anti-tumor effect and recurrence-free and overall survival.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Otorhinolaryngology,Surgery

Reference45 articles.

1. Nocini R., Molteni G., Mattiuzzi C., Lippi G. Updates on larynx cancer epidemiology. Chin J Cancer Res 2020;32(1):18—25. DOI: 10.21147/j.issn.1000-9604.2020.01.03;

2. Steuer C.E., El-Deiry M., Parks J.R. et al. An update on larynx cancer. CA Cancer J Clin 2017;67(1):31—50. DOI: 10.3322/caac.21386.

3. American Cancer Society. Cancer Facts and Figures 2019. Atlanta: American Cancer Society, 2019. Available online: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf

4. Kaprin A.D. The state of oncological care for the population in Russia in 2019. Moscow, 2017. 16 p. (In Russ.).

5. Kaprin A.D., Starinsky V.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow: P. A. Herzen Moscow State Medical Research Institute-branch of the Federal State Budgetary Institution “NMIRC” of the Ministry of Health of Russia, 2017 (In Russ.).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3